Full-Time

Clinical Trial Manager

Confirmed live in the last 24 hours

HeartFlow

HeartFlow

501-1,000 employees

Non-invasive cardiac testing for heart disease

Healthcare

Compensation Overview

$85k - $140kAnnually

+ Cash Bonus + Stock Options

Senior

Remote in USA + 1 more

More locations: Mountain View, CA, USA

The job can be performed remotely, but candidates may also work from Mountain View, California.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
Word/Pages/Docs
Google Cloud Platform
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides

You match the following HeartFlow's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Ability to work in a smaller team environment with a willing, all hands on deck attitude
  • Ability to manage multiple tasks and be comfortable working in an environment with shifting priorities
  • High attention to detail, accuracy, and quality and able to effectively prioritize multiple projects
  • Knowledge of ICH Guidelines, US FDA, and European clinical trial requirements and regulations
  • Excellent written and oral English communication skills required
  • Proficiency in computer programs and specifically in Microsoft office tools including Word, Excel and PowerPoint
  • Bachelor’s degree in science or health related field
  • Demonstrated 5 years minimum relevant experience required
Responsibilities
  • Participates in clinical research activities including management of clinical study sites, management of study documentation, vendor management, and completion of project management tasks
  • Develops clinical trial timelines, enrollment projections, and instructional materials in support of trial execution, including project, communication, monitoring, recruitment, risk mitigation, and contingency plans
  • Participates in and leads process improvement activities within the department and cross functionally, including SOP development
  • Conducts study start-up activities including the development of protocols, informed consent forms, source document worksheets, training presentations, etc.
  • Reviews site regulatory documents (informed consents, IRB approvals, research agreements) to ensure compliance with study requirements and GCPs
  • Maintains effective working relationships with investigators/investigational site research coordinators, and vendors including core labs and data management
  • Perform other duties as required for successfully completing studies, as necessary
Desired Qualifications
  • Experience in cardiovascular medical device clinical research a plus

HeartFlow provides a non-invasive cardiac test that helps visualize a patient's coronary arteries in detail. This technology allows physicians to diagnose and treat heart disease more effectively without the need for invasive procedures, which reduces risks for patients and costs for healthcare providers. HeartFlow's main product, the HeartFlow Analysis, includes various analyses such as FFRCT Analysis and Plaque Analysis, and has received FDA clearance for use in the United States, as well as approvals in the UK, Japan, and Canada. Unlike many competitors, HeartFlow focuses on providing a safer and more efficient diagnostic method for cardiovascular care. The company's goal is to enhance the quality of heart disease treatment by offering advanced technology that supports better decision-making for healthcare providers.

Company Size

501-1,000

Company Stage

Series F

Total Funding

$858.5M

Headquarters

Redwood City, California

Founded

2010

Simplify Jobs

Simplify's Take

What believers are saying

  • HeartFlow secured $215 million in Series F funding to scale operations and enhance products.
  • The GAMEFILM Registry collaboration expands HeartFlow's market by addressing unique cardiovascular risks.
  • HeartFlow's RoadMap Analysis increases adoption potential in clinical settings.

What critics are saying

  • Emerging AI-driven competitors could threaten HeartFlow's market share with similar technologies.
  • Algorithmic bias in AI models may lead to inaccurate diagnoses and legal liabilities.
  • Regulatory hurdles in international markets could delay HeartFlow's product adoption.

What makes HeartFlow unique

  • HeartFlow combines anatomy, physiology, and plaque analysis for comprehensive heart disease diagnostics.
  • HeartFlow's non-invasive FFRCT Analysis offers personalized 3D heart models for precise treatment.
  • HeartFlow's AI-driven technology aligns with updated AHA/ACC chest pain guidelines.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Stock Options

401(k) Company Match

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

0%
Hit Consultant
Jan 22nd, 2025
Heartflow And Boone Heart Institute Launch Gamefilm Registry To Study Heart Health In Retired Nfl Players

HeartFlow and Boone Heart Institute Launch GAMEFILM Registry to Study Heart Health in Retired NFL Players. by Fred Pennic 01/22/2025 Leave a Comment. What You Should Know: – HeartFlow, a global leader in AI-driven heart care solutions, and Boone Heart Institute, a renowned cardiovascular care provider in Denver, today announced the launch of the GAMEFILM Registry. – GAMEFILM Registry will utilize advanced imaging and AI technology to assess and better understand coronary artery disease (CAD) risk in retired National Football League (NFL) players.Understanding the Unique Cardiovascular Risks of Retired NFL PlayersCardiovascular disease remains the leading cause of death globally. Despite advancements in diagnostics, many heart attacks and strokes occur in individuals without prior symptoms. Early identification of high-risk individuals is critical for effective prevention and treatment. Retired NFL players often face unique cardiovascular health challenges due to the intense physical demands of their careers

GlobeNewswire
Oct 18th, 2024
HeartFlow Announces New Category I CPT Code from the American Medical Association for AI-Enabled Plaque Analysis to Assess Risk for Coronary Artery Disease

HeartFlow announces new Category I CPT code from the American Medical Association for ai-enabled Plaque Analysis to assess risk for coronary artery disease.

Medical Device Network
Jul 19th, 2024
HeartFlow launches plaque analysis platform for coronary artery disease

HeartFlow launches plaque analysis platform for coronary artery disease.

Stockhouse
Nov 1st, 2023
Corcept Appoints Monica Tellado as President, Emerging Markets

Corcept appoints Monica Tellado as President, Emerging Markets.

Aunt Minnie
Apr 19th, 2023
HeartFlow launches RoadMap Analysis software

Cardiovascular artificial intelligence (AI) software developer HeartFlow has released its RoadMap software for identifying stenoses in the coronary arteries on CT exams.

DiCardiology
Apr 18th, 2023
New HeartFlow RoadMap Analysis Now Available in U.S. to Assist CT Readers in Identifying Coronary Artery Narrowings | DAIC

HeartFlow, Inc. announced the launch of the RoadMap analysis, a new AI -enabled product that assists CT readers to accurately*, efficiently, and consistently identify stenoses in the coronary arteries.

GlobeNewswire
Apr 17th, 2023
New Heartflow Roadmap™ Analysis Now Available In U.S. To

MOUNTAIN VIEW, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- HeartFlow, Inc. today announced the launch of the RoadMap analysis, a new AI-enabled product that assists CT readers to accurately*, efficiently, and consistently identify stenoses in the coronary arteries. With its expanded product portfolio, HeartFlow is now the only company to offer anatomical and physiological visualization of the coronary arteries to help improve heart disease diagnosis and enable physicians to guide treatment decisions. Heart disease is the leading cause of death in the United States.1 Despite advancements in the diagnosis and treatment of coronary artery disease (CAD), the most common heart disease, the complexities of symptoms and the limitations of traditional testing can make it challenging for physicians to correctly identify the condition. The RoadMap analysis is designed to help improve CAD diagnosis by providing CT readers with a 2D visual that shows the location and severity of anatomic narrowings in the coronary arteries. It has been shown to provide accurate*, reproducible results and helps facilitate standardized and high-quality CT interpretation.2 The RoadMap analysis, alongside HeartFlow’s FFRCT, aligns with the recently updated AHA/ACC chest pain guidelines and enhances existing diagnostic workflows by guiding treatment decisions and improving patient outcomes.3 “As a leader in non-invasive diagnosis of CAD, HeartFlow is intimately familiar with the challenges associated with diagnosing heart disease,” said John Farquhar, Chief Executive Officer of HeartFlow

Benzinga
Apr 6th, 2023
Heartflow, Leader In Revolutionizing Precision Heart Care, Closes $215 Million In Series F Funding Led By Bain Capital Life Sciences

MOUNTAIN VIEW, Calif., April 06, 2023 (GLOBE NEWSWIRE) -- HeartFlow, Inc., the leader in revolutionizing precision heart care, today announced the close of a $215 million Series F funding round by its parent company HeartFlow Holding, Inc., led by Bain Capital Life Sciences with participation from new investor Janus Henderson Investors, and existing investors including Baillie Gifford, Capricorn Investment Group, Hayfin Capital Management, HealthCor, Martis Capital, USVP and Wellington Management. This new funding will enable HeartFlow to meet the growing demand for its commercial products, support a robust body of growing clinical evidence and advance its comprehensive product portfolio to help physicians to diagnose coronary artery disease (CAD) and guide their treatment decisions.The financing follows a period of remarkable growth for HeartFlow. Coronary computed tomography angiography (CCTA) and FFR CT have already been recognized by the recent ACC/AHA Chest Pain Guidelines, and HeartFlow's FFR CT technology is covered by 100% of Medicare and over 98% of commercial payers. With the recent FDA clearance of new products, the company is the first and only company to provide non-invasive coronary artery anatomy (RoadMap™ analysis), physiology (HeartFlow® FFR CT ) and plaque information (Plaque analysis) based on CCTA. These products enable physicians to gain more understanding of a patient's CAD and are the most comprehensive approach to predict risk of a heart attack.1"HeartFlow has built a strong intellectual property portfolio, brought to market the only combined anatomy, physiology and plaque analysis to help diagnose and treat heart disease, and is now in over 725 hospital systems worldwide with over 180,000 patients served to date," said John Farquhar, Chief Executive Officer of HeartFlow. "The oversubscription of our Series F funding round, particularly in the current market backdrop, is a strong validation of our technology, our team and the opportunity in front of us

MPO Magazine
Apr 6th, 2023
HeartFlow Closes $215 Million Series F Funding Round | Medical Product Outsourcing

HeartFlow Inc., a leader in precision heart care, has closed a $215 million Series F funding round by its parent company, HeartFlow Holding Inc. led by Bain Capital Life Sciences with participation from new investor, Janus Henderson Investors, and existing investors, including Baillie Gifford, Capricorn Investment Group, Hayfin Capital Management, HealthCor, Martis Capital, USVP and Wellington Management.

GlobeNewswire
Apr 6th, 2023
HeartFlow, Leader in Revolutionizing Precision Heart Care, Closes $215 Million in Series F Funding Led by Bain Capital Life Sciences

Financing will further drive commercial scale for HeartFlow’s AI-enabled portfolio of precision heart care products...

GlobeNewswire
Apr 4th, 2022
HeartFlow, Inc. hired Monica Tellado as Chief Financial Officer on Apr 4th 22'.

HeartFlow, Inc., the leader in revolutionizing precision heart care, today announced that Monica Tellado has been appointed Chief Financial Officer (CFO), effective April 4, 2022.